Zynlonta market seen growing on rising lymphoma cases and trial activity
The Business Research Company says the Zynlonta market is poised for continued expansion through 2035, driven by rising lymphoma cases, more clinical trials and wider use of antibody-drug conjugates. North America held the largest share in 2025, while the report flags growth opportunities across major global regions.
Why it matters: - Zynlonta is positioned as a targeted therapy for relapsed or refractory large B-cell lymphoma, a cancer area with growing need for more precise treatment options. - The market outlook signals continued demand for antibody-drug conjugate therapies as oncology treatment moves toward personalized care and combination regimens.
What happened: - The Business Research Company released its 2026 Zynlonta market report covering market size, trends and global forecasts for 2026-2035. - The report says the Zynlonta market is expected to keep growing, supported by scientific progress and broader clinical use. - North America held the largest share of the global Zynlonta market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample and the full report are available online through the company’s sample request page and the full market report.
The details: - Zynlonta, or loncastuximab tesirine-lpyl, is an antibody-drug conjugate used to treat relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, after at least two systemic therapy regimens. - The drug works by delivering chemotherapy directly to cancerous B cells. - Historical market growth was supported by rising hematological malignancy cases, higher failure rates for traditional chemotherapy, growth in specialized oncology centers, improved diagnostic tools for lymphoma types and wider use of ADC therapies. - Future growth drivers include next-generation ADCs, increased demand for personalized cancer treatments, expansion of targeted oncology pipelines, higher investment in biologic cancer therapies and more use of combination therapies. - Key trends include broader adoption of antibody-drug conjugates, more focused treatment for B-cell lymphomas, greater emphasis on precision oncology drugs, growth in hospital-based oncology infusion services and more attention to relapsed and refractory cancers. - The American Cancer Society reported US lymphoma cases rising from 89,010 in 2022 to 89,380 in 2023. - The Association of the British Pharmaceutical Industry reported UK pharmaceutical trials rising from 411 in 2022 to 426 in 2023.
Between the lines: - The report ties Zynlonta’s growth story to two broader oncology shifts: more patients needing second-line or later treatment and more confidence in targeted therapies backed by clinical evidence. - North America’s lead suggests the market is still most mature in regions with strong oncology infrastructure, while other regions may offer future upside as diagnosis and treatment access improve. - The report’s added scoring tools, TAM analysis and hotspot graphics indicate a more investor-oriented framing of the market opportunity.
What's next: - The report expects market growth to continue as more next-generation ADCs enter development and more combination regimens reach clinical use. - Wider adoption of precision oncology and hospital infusion services could expand Zynlonta’s reach in the coming years. - The Business Research Company says its 2026 report suite now includes market attractiveness scoring, company scoring matrices, Excel dashboards, hotspot infographics and updated trend analysis.
The bottom line: - Zynlonta’s market outlook is being driven by rising lymphoma incidence, growing clinical trial activity and a larger shift toward targeted cancer therapies.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Culture Zone! UK
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.